Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout

Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating.

Seeking Alpha • Aug 12, 2026

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million. Deal centers around Actio's lead drug for KCNT+ epilepsy, ABS-1230.

CNBC • Aug 11, 2026

Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio

Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at ​up to $1.32 billion, adding an experimental treatment for ‌a rare inherited form of epilepsy that has no approved therapies.

Reuters • Aug 10, 2026

Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy Leverages Jazz development expertise and commercial strength in rare and severe epilepsies Transaction includes $820 million upfront payment  DUBLIN and SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Actio Biosciences, Inc. (Actio Biosciences) today announced the companies have entered into a definitive agreement for Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration. Actio Biosciences' lead clinical asset is ABS-1230, a novel, first-in-class small molecule precision therapy KCNT1 ion channel inhibitor.

PRNewsWire • Aug 10, 2026

Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects

Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Zacks Investment Research • Aug 10, 2026

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 7, 2026

JAZZ vs. TECH: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Aug 6, 2026

Jazz Pharmaceuticals' Re-Rating Story Has Legs

Jazz Pharmaceuticals has delivered strong year-to-date performance, raising full-year revenue guidance. JAZZ's oxybate franchise, led by Xywav, continues double-digit growth despite the full generic Xyrem launch, driving a significant guidance increase. Ziihera's potential first-line GEA approval this month could unlock a large new revenue stream and accelerate sequential growth.

Seeking Alpha • Aug 5, 2026

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) on Monday reported better-than-expected second-quarter sales results and raised its FY26 sales guidance above estimates.

Benzinga • Aug 4, 2026

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.

Zacks Investment Research • Aug 4, 2026